CRYBG1

Last update 08 May 2025

Basic Info

Synonyms

Absent in melanoma 1 protein, AIM1, Beta/gamma crystallin domain-containing protein 1

+ [3]

Introduction

May function as suppressor of malignant melanoma. It may exert its effects through interactions with the cytoskeleton.

100 Clinical Results associated with CRYBG1

100 Translational Medicine associated with CRYBG1

0 Patents (Medical) associated with CRYBG1

223

Literatures (Medical) associated with CRYBG1

01 May 2025·International Journal of Biological Macromolecules

Functional characterization and protein engineering of glycosyltransferase for 2”-O-xylosylation of ginsenoside Rg3

Article

Author: Li, Pengfei ; Pu, Zhongji ; Guo, Zhihan ; Ding, Lili ; Lai, Guanxue ; Wang, Rufeng ; Wang, Ziyan ; Wang, Zhengtao ; Huang, Chaokang ; Niu, Tengfei ; Yang, Li

The limited abundance of xylosylated ginsenosides and the lack of efficient biocatalysts hinder their pharmacological exploration. This study identified a 2"-O-xylosyltransferase (PnUGT57) from Panax notoginseng that catalyzes the conversion of ginsenoside Rg3 to notoginsenoside ST4. Wild-type PnUGT57 preferred UDP-xylose over UDP-glucose and UDP-rhamnose and displayed limited thermostability (t_1/2 = 6.73 h at 30 °C). To enhance UDP-xylose specificity, sequence-guided mutagenesis generated the C140A variant, which achieved remarkable UDP-xylose specificity (100 % conversion) with a 1.34-fold increase in catalytic efficiency while showing weak activity toward UDP-glucose (8.7 %) and UDP-rhamnose (5.2 %) activity. The F367A mutant possesses only xylosyltransferase activity but with reduced catalytic efficiency (0.3-fold of the WT). Molecular docking revealed that the enhanced UDP-xylose specificity in C140A and F367A resulted from the loss of key hydrogen bonding and hydrophobic interactions. To improve thermostability, computational design produced a triple mutant (P101S/L200C/G255D) with an 8.58-fold longer half-life (57.76 h), attributed to optimized surface charge distribution and improved hydration layer formation, as confirmed by molecular dynamics simulation. The combinatorial mutant C140A/P101S/L200C/G255D synergistically improved UDP-xylose specificity, thermostability, and catalytic efficiency, enabling efficient ST4 biosynthesis. This study elucidates the catalytic mechanism of PnUGT57 and presents engineered variants as promising biocatalysts for sustainable ginsenoside production.

01 Jan 2025·Veterinary Medicine and Science

Global Prevalence and Subtype Distribution of Blastocystis sp. in Rodent Populations: A Systematic Review and Meta‐Analysis

Review

Author: Asghari, Ali ; Sadat‐Madani, Parisa ; Karampour, Amin ; Nazem‐Sadati, Seyedeh‐Sara ; Farzam, Amir

AbstractBackgroundThe present systematic review and meta‐analysis aimed to gather and analyse global data on the prevalence, subtypes (STs) distribution and zoonotic potential of Blastocystis sp. in rodents.MethodsA systematic literature search was performed across multiple databases (PubMed, Scopus, Web of Science and ProQuest) for studies published by 23 July 2024. The analysis included 34 studies/78 datasets, comprising 5661 samples from various rodent species across 15 countries. Statistical analyses were performed using comprehensive meta‐analysis (CMA) software, employing a random‐effects model to estimate pooled prevalence and 95% confidence intervals (CIs) and the I2 index for assessing heterogeneity.ResultsThis review found that 16% (95% CI: 12.6%–20.2%) of rodents worldwide were infected with Blastocystis sp. Voles and squirrels exhibited the highest infection rates at 29.8% (95% CI: 14.7%–51%) and 28.8% (95% CI: 14.4%–49.2%), whereas civets and porcupines had the lowest rates at 9.5% (95% CI: 6.6%–13.6%) and 7.1% (95% CI: 3.3%–14.7%), respectively. The findings indicated that rodents can host various Blastocystis sp. STs (ST1–ST8, ST10, ST13, ST15, ST17), with several (ST1–ST8 and ST10) having zoonotic potential. Globally, ST4, ST5, ST1 and ST3 were the most commonly reported STs in rodents. China and the UK showed the highest ST diversity in rodents, with 10 (ST1‐ST7, ST10, ST13, ST17) and 7 (ST1‐ST5, ST10, ST15) distinct STs, respectively. ST6, ST7 and ST13 were unique to China, whereas ST15 was found only in the United Kingdom. Squirrels, rats, mice and voles had the highest ST diversity of Blastocystis sp., with 8, 7, 5 and 5 distinct STs, respectively. Notably, ST6 and ST13 were unique to squirrels, ST7 only appeared in rats, and ST15 was found only in voles. Most ST1, ST3–ST5 and ST17 came from Asia. ST6, ST7 and ST13 were also isolated there, whereas ST15 was only found in Europe. ST17 was reported in Africa, ST4 and ST17 in North America, and ST1–ST3 and ST8 in South America.ConclusionsThis review emphasizes the widespread presence of Blastocystis sp. in rodent populations globally, underscoring the need for continued surveillance and research into its zoonotic potential.

01 Nov 2024·American Journal of Transplantation

BK polyomavirus serotype-specific antibody responses in blood donors and kidney transplant recipients with and without new-onset BK polyomavirus-DNAemia: A Swiss Transplant Cohort Study

Article

Author: De Geest, Sabina ; Reineke, David ; Müller-Arndt, Ulrike ; Goossens, Nicolas ; Rick, Juliane ; Müller, Jelena ; Haidar, Fadi ; Berzigotti, Annalisa ; Hirt, Patricia ; Lamoth, Frédéric ; Rothlin, Silvia ; Müller, Nicolas ; Akbari Bani, Dorssa ; Frossard, Jaromil ; Stirnimann, Guido ; Dreifuss, Joëlle Lynn ; Sengstag, Thierry ; Rössler, Fabian ; Schneidawind, Dominik ; Hirsch, Hans H. ; Van Delden, Christian ; Amico, Patrizia ; Ferrari-Lacraz, Sylvie ; Lehmann, Roger ; Marti, Hans-Peter ; Sidler, Daniel ; McLin, Valérie ; Mueller, Nicolas J. ; Leuzinger, Karoline ; Kremer, Andreas ; Hofbauer, Günther ; Manuel, Oriol ; Hess, Christoph ; Pascual, Manuel ; Cairoli, Anne ; Weissbach, Fabian H. ; Neofytos, Dionysios ; Hillenbrand, Caroline A. ; Bochud, Pierre-Yves ; Berger, Christoph ; Kaur, Amandeep ; Dickenmann, Michael ; Wilhelm, Maud ; Simonetta, Federico ; Bachofner, Adrian ; Venetz, Jean-Pierre ; Chalandon, Yves ; Fehr, Thomas ; De Seigneux, Sophie ; Pazeller, Rosmarie ; Wernli, Marion ; Nilsson, Jakob ; Wilhelm, Markus ; L'Huillier, Arnaud ; Stürzinger, Ueli ; Follonier, Océane ; Schaub, Stefan ; Huynh-Do, Uyen ; Yerly, Patrick ; Vionnet, Julien ; Kuhn, Christian ; Branca, Sanda ; Merçay, Aurélia ; Borner, Petra ; Binet, Isabelle ; Martinelli, Michele ; Banz, Vanessa ; Binet, Françoise-Isabelle ; Wehmeier, Caroline ; Nägeli, Mirjam ; Khanna, Nina ; Mettler, Karin ; Schachtner, Thomas ; Steiger, Jürg ; Golshayan, Dela ; Hirzel, Cédric ; Duchosal, Michel ; Krueger, Thorsten ; Beckmann, Sonja ; Flammer, Andreas ; Immer, Franz ; Laesser, Bettina ; Berishvili, Ekaterine ; Catana, Emmanuelle ; Hoessly, Linard ; Compagnon, Philippe ; Schuurmans, Macé ; Beldi, Guido ; Schwab, Simon ; Hillinger, Sven ; Halter, Jürg ; Koller, Michael ; Villard, Jean ; Mellac, Katell ; Leichtle, Alexander

BK polyomavirus (BKPyV) causes premature renal failure in 10% to 30% of kidney transplant recipients (KTRs). Current guidelines recommend screening for new-onset BKPyV-DNAemia/nephropathy and reducing immunosuppression to regain BKPyV-specific immune control. Because BKPyV encompasses 4 major genotype (gt)-encoded serotypes (st1,-2,-3,-4), st-specific antibodies may inform the risk and course of BKPyV-DNAemia/nephropathy. Using BKPyV st-virus-like particle (VLP) enzyme-linked immunosorbent assay, we analyzed plasma from 399 blood donors (BDs) and 428 KTRs (134 KTR-cases with BKPyV-DNAemia, 294 KTR-controls). BDs were anti-BKPyV-VLP immunoglobulin G-seropositive in 85% compared to 93% of KTRs at the timepoint at transplantation (T0) (P < .001). Anti-st1 was predominant in both groups followed by anti-st4, anti-st2, and anti-st3. Antibody levels and quadruple sero-reactivity at T0 were higher in KTR-controls than in KTR-cases (P = .026) or in BDs (P < .001). In KTR-cases, anti-st increased posttransplant (P < .0001) and independently of ongoing or cleared BKPyV-DNAemia. However, anti-st levels were significantly higher at T0 in KTR-cases able to clear at timepoint 6-month posttransplant or timepoint 12-month posttransplant. In 34 KTR-cases with deep genome sequencing, BKPyV-gtI was predominant, and anti-st1 and st1-neutralizing antibodies were significantly lower at T0 than in KTR-controls. Thus, BKPyV st-specific antibody levels at transplantation might reflect gt/st-BKPyV-specific immunity clearing or preventing BKPyV-DNAemia in KTR-cases or KTR-controls, respectively. Accordingly, active or passive immunization may be most efficient pretransplant or early posttransplant.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CRYBG1

Basic Info

Related

Analysis